Clinical Trial Detail

NCT ID NCT02925104
Title A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

Capmatinib

Age Groups: child senior adult

No variant requirements are available.